Exploring Polypharmacology Using a ROCS-Based Target Fishing Approach

Polypharmacology has emerged as a new theme in drug discovery. In this paper, we studied polypharmacology using a ligand-based target fishing (LBTF) protocol. To implement the protocol, we first generated a chemogenomic database that links individual protein targets with a specified set of drugs or target representatives. Target profiles were then generated for a given query molecule by computing maximal shape/chemistry overlap between the query molecule and the drug sets assigned to each protein target. The overlap was computed using the program ROCS (Rapid Overlay of Chemical Structures). We validated this approach using the Directory of Useful Decoys (DUD). DUD contains 2950 active compounds, each with 36 property-matched decoys, against 40 protein targets. We chose a set of known drugs to represent each DUD target, and we carried out ligand-based virtual screens using data sets of DUD actives seeded into DUD decoys for each target. We computed Receiver Operator Characteristic (ROC) curves and associated area under the curve (AUC) values. For the majority of targets studied, the AUC values were significantly better than for the case of a random selection of compounds. In a second test, the method successfully identified off-targets for drugs such as rimantadine, propranolol, and domperidone that were consistent with those identified by recent experiments. The results from our ROCS-based target fishing approach are promising and have potential application in drug repurposing for single and multiple targets, identifying targets for orphan compounds, and adverse effect prediction.

[1]  G Wolber,et al.  Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. , 2008, Current medicinal chemistry.

[2]  J. Mestres,et al.  A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.

[3]  Didier Rognan,et al.  Structure‐Based Approaches to Target Fishing and Ligand Profiling , 2010, Molecular informatics.

[4]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[5]  Christine Humblet,et al.  Computation of 3D queries for ROCS based virtual screens , 2009, J. Comput. Aided Mol. Des..

[6]  A. Bender,et al.  In silico target fishing: Predicting biological targets from chemical structure , 2006 .

[7]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[8]  G. Klebe,et al.  Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. , 2004, Journal of medicinal chemistry.

[9]  Hugo A Katus,et al.  hERG: protein trafficking and potential for therapy and drug side effects. , 2010, Current opinion in drug discovery & development.

[10]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[11]  John R Cashman,et al.  Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. , 2009, Journal of medicinal chemistry.

[12]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[13]  Lin He,et al.  SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome , 2009, Nucleic Acids Res..

[14]  H. L. Morgan The Generation of a Unique Machine Description for Chemical Structures-A Technique Developed at Chemical Abstracts Service. , 1965 .

[15]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[16]  David Rogers,et al.  Cheminformatics analysis and learning in a data pipelining environment , 2006, Molecular Diversity.

[17]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[18]  J. Palacios,et al.  Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. , 1999, European journal of pharmacology.

[19]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[20]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[21]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[22]  Liwei Li,et al.  BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome , 2009, Nucleic Acids Res..

[23]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[24]  David B Jackson,et al.  Drug profiling: knowing where it hits. , 2010, Drug discovery today.

[25]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[26]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[27]  I. van Wijngaarden,et al.  2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. , 1987, Journal of medicinal chemistry.

[28]  Nanda Ghoshal,et al.  Hybrid Structure-Based Virtual Screening Protocol for the Identification of Novel BACE1 Inhibitors , 2009, J. Chem. Inf. Model..

[29]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[30]  C. Laggner,et al.  Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.

[31]  Jérôme Hert,et al.  Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures , 2004, J. Chem. Inf. Model..

[32]  K. Fan,et al.  Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[33]  J Edelson,et al.  Interactions of chlorphenesin and divalent metal ions with phosphodiesterase. , 1976, Archives internationales de pharmacodynamie et de therapie.

[34]  Katya Tsaioun,et al.  ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective , 2009, BMC neurology.

[35]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[36]  J. Jenkins,et al.  Prediction of Biological Targets for Compounds Using Multiple‐Category Bayesian Models Trained on Chemogenomics Databases. , 2006 .

[37]  William Loging,et al.  High-throughput electronic biology: mining information for drug discovery , 2007, Nature Reviews Drug Discovery.

[38]  Xiaozhou Yao,et al.  Propranolol inhibits the human ether-a-go-go-related gene potassium channels. , 2005, European journal of pharmacology.

[39]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[40]  E. van Luijtelaar,et al.  Rat models of genetic absence epilepsy: what do EEG spike-wave discharges tell us about drug effects? , 2002, Methods and findings in experimental and clinical pharmacology.

[41]  Scott Boyer,et al.  Ligand-Based Approach to In Silico Pharmacology: Nuclear Receptor Profiling , 2006, J. Chem. Inf. Model..

[42]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[43]  Peter Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2007, Nature Reviews Drug Discovery.

[44]  D. Wong,et al.  Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. , 1983, Biochemical pharmacology.

[45]  C. Singer,et al.  Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series , 2005, Movement disorders : official journal of the Movement Disorder Society.

[46]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[47]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[48]  C. Humblet,et al.  Modeling G protein‐coupled receptors for structure‐based drug discovery using low‐frequency normal modes for refinement of homology models: Application to H3 antagonists , 2010, Proteins.

[49]  Scott Boyer,et al.  Ligand-Based Approach to in Silico Pharmacology: Nuclear Receptor Profiling. , 2007 .

[50]  Xiaomin Luo,et al.  TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..